Extension of Time to File SOU

PYLARIFY

Progenics Pharmaceuticals, Inc.

Request for Extension of Time to File a Statement of Use

PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 88647018
LAW OFFICE ASSIGNED LAW OFFICE 103
MARK SECTION
MARK PYLARIFY (see, http://uspto.report/TM/88647018/mark.png)
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT PYLARIFY
OWNER SECTION (current)
NAME Progenics Pharmaceuticals, Inc.
INTERNAL ADDRESS One World Trade Center
MAILING ADDRESS 47th Floor Suite J
CITY New York
STATE New York
ZIP/POSTAL CODE 10007
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
OWNER SECTION (proposed)
NAME Progenics Pharmaceuticals, Inc.
INTERNAL ADDRESS One World Trade Center
MAILING ADDRESS 47th Floor Suite J
CITY New York
STATE New York
ZIP/POSTAL CODE 10007
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME Douglas R. Wolf
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE drwtrademarks@wolfgreenfield.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
CORRESPONDENCE INFORMATION (proposed)
NAME Douglas R. Wolf
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE drwtrademarks@wolfgreenfield.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
DOCKET/REFERENCE NUMBER P11762002800
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 042
CURRENT IDENTIFICATION Scientific research and development in the nature of research, development and preparation of pharmaceutical drugs and imaging agents for medical use; Providing temporary use of non-downloadable medical imaging software for the identification, quantification, diagnosis, prevention, treatment and monitoring of cancer
GOODS OR SERVICES KEEP ALL LISTED
INTERNATIONAL CLASS 044
CURRENT IDENTIFICATION Providing medical testing services and information in the field of cancer diagnosis, treatment and prevention; Web-based medical testing for identification, quantification, diagnostic or treatment purposes in the field of cancer; providing medical information in the field of cancer identification, diagnosis, treatment and prevention; medical imaging services
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 2
ONGOING EFFORT product or service research or development ; market research
ALLOWANCE MAIL DATE 04/21/2020
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 2
SUBTOTAL AMOUNT [EXTENSION FEE] 250
TOTAL AMOUNT 250
SIGNATURE SECTION
SIGNATURE /drw/
SIGNATORY'S NAME Douglas R. Wolf
SIGNATORY'S POSITION Attorney of Record
DATE SIGNED 04/09/2021
SIGNATORY'S PHONE NUMBER 617-646-8000
SIGNATURE METHOD Sent to third party for signature
FILING INFORMATION
SUBMIT DATE Fri Apr 09 12:58:03 ET 2021
TEAS STAMP USPTO/ESU-XX.XXX.XX.X-202
10409125803310590-8864701
8-770b33541f9542e6861e539
d7b813c8d3f4496273f9b5de2
8c8d66a76a69f3823-CC-5800
1885-20210409125119598062



PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: PYLARIFY (see, http://uspto.report/TM/88647018/mark.png)
SERIAL NUMBER: 88647018

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Progenics Pharmaceuticals, Inc., having an address of
      One World Trade Center
      47th Floor Suite J
      New York, New York 10007
      United States
      Email: XXXX
Proposed: Progenics Pharmaceuticals, Inc., having an address of
      One World Trade Center
      47th Floor Suite J
      New York, New York 10007
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 04/21/2020.

For International Class 042:
Current identification: Scientific research and development in the nature of research, development and preparation of pharmaceutical drugs and imaging agents for medical use; Providing temporary use of non-downloadable medical imaging software for the identification, quantification, diagnosis, prevention, treatment and monitoring of cancer

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


For International Class 044:
Current identification: Providing medical testing services and information in the field of cancer diagnosis, treatment and prevention; Web-based medical testing for identification, quantification, diagnostic or treatment purposes in the field of cancer; providing medical information in the field of cancer identification, diagnosis, treatment and prevention; medical imaging services

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development ; market research

Correspondence Information (current):
      Douglas R. Wolf
      PRIMARY EMAIL FOR CORRESPONDENCE: drwtrademarks@wolfgreenfield.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

Correspondence Information (proposed):
      Douglas R. Wolf
      PRIMARY EMAIL FOR CORRESPONDENCE: drwtrademarks@wolfgreenfield.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $250 will be submitted with the form, representing payment for 2 classes.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /drw/      Date Signed: 04/09/2021
Signatory's Name: Douglas R. Wolf
Signatory's Position: Attorney of Record
Signatory's Phone: 617-646-8000
Signature method: Sent to third party for signature

PAYMENT: 88647018
PAYMENT DATE: 04/09/2021

Serial Number: 88647018
Internet Transmission Date: Fri Apr 09 12:58:03 ET 2021
TEAS Stamp: USPTO/ESU-XX.XXX.XX.X-202104091258033105
90-88647018-770b33541f9542e6861e539d7b81
3c8d3f4496273f9b5de28c8d66a76a69f3823-CC
-58001885-20210409125119598062




uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed